Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC).

摘要: NSCLC accounts for 80% of all cases lung cancer, which is the leading cause cancer mortality. The majority patients present with advanced, unresectable disease, remains incurable. In advanced chemotherapy platinum (cisplatin or carboplatin) in combination a third-generation cytotoxic drug (vinorelbine, gemcitabine, paclitaxel, docetaxel) can provide modest improvement survival without impairing quality life. chemotherapy-naive, non-squamous patients, bevacizumab was shown to produce better outcomes than alone. Response rates 20%-40% now be expected, median 8-11 months and 1-year rate 30%-40%. second-line treatment, docetaxel has superiority best supportive care terms A pooled analysis comparing administered weekly versus 3-weekly found similar between schedules non-significant reduction febrile neutropenia regimen. Pemetrexed, multitargeted antifolate agent, clear activity several tumors, including mesothelioma NSCLC. phase III trial, treatment pemetrexed demonstrated overall comparable docetaxel, more manageable toxicity profile.